Neurology:CRP和CRP基因单核苷酸多态性均与卒中发生和再发相关

2016-01-21 phylis 译 MedSci原创

目的:调查缺血性脑卒中患者脑血管病的遗传因素及生物标志物的变化。方法:维生素干预预防脑卒中试验(VISP)是一项补充B族维生素预防再发性卒中,心肌梗死或死亡的随机,对照,临床试验。VISP收集基线时C反应性蛋白(CRP)、纤维蛋白原、肌酐、凝血酶原片段F1 +2、凝血酶抗凝血酶复合物,及治疗前的血浆血栓调节蛋白。对这些特征进行基因组范围内的关联扫描,并进行后续的复制分析。结果:研究者在检测VISP

目的:调查缺血性脑卒中患者脑血管病的遗传因素及生物标志物的变化。

方法:维生素干预预防脑卒中试验(VISP)是一项补充B族维生素,预防再发性卒中、心肌梗死或死亡的随机对照临床试验。VISP收集基线时C反应性蛋白(CRP)、纤维蛋白原、肌酐、凝血酶原片段F1 +2、凝血酶抗凝血酶复合物,及治疗前的血浆血栓调节蛋白。对这些特征进行基因组范围内的关联扫描,并进行后续的复制分析。

结果:研究者在检测VISP 中2100名受试者,CRP单核苷酸多态性(SNP)和循环CRP水平的相关性。(最相关的SNP,rs2592902)。研究者发现了AKR1D1位点(rs2589998,接近全基因组的意义)与CRP水平相关,AKR1D1位点也是一种CRP基因表达的数量性状基因。研究者重复先前确定的纤维蛋白原在FGB和LEPR基因SNP的相关性。CRP相关的SNPs和CRP水平与VISP中缺血性卒中发生和卒中复发的风险以及在METASTROKE中特定卒中亚型的发生显著相关。纤维蛋白原水平与VISP中卒中再发相关,纤维蛋白原相关的单核苷酸多态性与卒中再发不相关。

结论:研究数据确定了卒中人群中炎症和止血生物标志物的一个遗传因素。此外,研究结果表明,基因影响卒中后循环CRP的水平及缺血性卒中发生和卒中再发的风险。这些数据加深了基因对缺血性卒中风险和生物标记物的影响的理解,对临床风险评估有着重要作用。

原文出处:

Williams SR, Hsu FC, Keene KL, et al. Shared genetic susceptibility of vascular-related biomarkers with ischemic and recurrent stroke. Neurology. 2015 Dec 30.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1945603, encodeId=7f7d194560352, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu May 05 10:21:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999641, encodeId=b9871999641b7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Oct 24 09:21:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61019, encodeId=d8e861019d3, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:11:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61020, encodeId=10c76102017, content=有新意, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:11:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269581, encodeId=59b512695811a, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471740, encodeId=d33214e17408b, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629200, encodeId=c995162920071, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
    2016-05-05 xsm918
  2. [GetPortalCommentsPageByObjectIdResponse(id=1945603, encodeId=7f7d194560352, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu May 05 10:21:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999641, encodeId=b9871999641b7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Oct 24 09:21:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61019, encodeId=d8e861019d3, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:11:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61020, encodeId=10c76102017, content=有新意, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:11:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269581, encodeId=59b512695811a, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471740, encodeId=d33214e17408b, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629200, encodeId=c995162920071, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
    2016-10-24 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1945603, encodeId=7f7d194560352, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu May 05 10:21:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999641, encodeId=b9871999641b7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Oct 24 09:21:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61019, encodeId=d8e861019d3, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:11:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61020, encodeId=10c76102017, content=有新意, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:11:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269581, encodeId=59b512695811a, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471740, encodeId=d33214e17408b, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629200, encodeId=c995162920071, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
    2016-01-27 李继凯

    好好学习一下

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1945603, encodeId=7f7d194560352, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu May 05 10:21:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999641, encodeId=b9871999641b7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Oct 24 09:21:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61019, encodeId=d8e861019d3, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:11:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61020, encodeId=10c76102017, content=有新意, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:11:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269581, encodeId=59b512695811a, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471740, encodeId=d33214e17408b, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629200, encodeId=c995162920071, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
    2016-01-27 李继凯

    有新意

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1945603, encodeId=7f7d194560352, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu May 05 10:21:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999641, encodeId=b9871999641b7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Oct 24 09:21:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61019, encodeId=d8e861019d3, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:11:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61020, encodeId=10c76102017, content=有新意, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:11:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269581, encodeId=59b512695811a, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471740, encodeId=d33214e17408b, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629200, encodeId=c995162920071, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
    2016-01-23 rebeccajiejie
  6. [GetPortalCommentsPageByObjectIdResponse(id=1945603, encodeId=7f7d194560352, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu May 05 10:21:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999641, encodeId=b9871999641b7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Oct 24 09:21:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61019, encodeId=d8e861019d3, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:11:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61020, encodeId=10c76102017, content=有新意, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:11:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269581, encodeId=59b512695811a, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471740, encodeId=d33214e17408b, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629200, encodeId=c995162920071, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1945603, encodeId=7f7d194560352, content=<a href='/topic/show?id=a9fa62150e8' target=_blank style='color:#2F92EE;'>#核苷酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62150, encryptionId=a9fa62150e8, topicName=核苷酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49cf452, createdName=xsm918, createdTime=Thu May 05 10:21:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999641, encodeId=b9871999641b7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Oct 24 09:21:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61019, encodeId=d8e861019d3, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:11:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=61020, encodeId=10c76102017, content=有新意, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Wed Jan 27 18:11:00 CST 2016, time=2016-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269581, encodeId=59b512695811a, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471740, encodeId=d33214e17408b, content=<a href='/topic/show?id=f30b362128a' target=_blank style='color:#2F92EE;'>#单核苷酸多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36212, encryptionId=f30b362128a, topicName=单核苷酸多态性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f897130202, createdName=mxj1971614, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629200, encodeId=c995162920071, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Sat Jan 23 03:21:00 CST 2016, time=2016-01-23, status=1, ipAttribution=)]
    2016-01-23 xzw120

相关资讯

Clin Chim Acta:基线C反应蛋白较高与缺血性卒中风险增加相关

背景:有关超敏C-反应蛋白(hs-CRP)和卒中的风险之间的研究结果是相互矛盾的。目标:为确定基线hs-CRP升高的是否是不同类型的卒中的独立危险因素。方法:系统搜索PubMed、EMBASE、Cochrane图书馆、中国知网和万方数据库中2015年1月前发表的前瞻性观察性研究。研究报告超敏c反应蛋白水平和hs-CRP和不同卒中亚型的水平和校正风险评估值。总结果用校正风险比(RR)来表示,及相应的

Am Heart J: IL-6和CRP是房颤患者死亡和心血管事件发生的危险因素(RE-LY研究)

背景:炎症与心血管疾病和房颤(AF)相关。这项研究中,研究者评估房颤患者炎症标志物和未来心血管事件的发生的相关性。方法:随机化分析IL-6,CRP(n= 6187)和纤维蛋白原(n = 4893)。应用Cox模型和C-statistics评估预后。结果:校正临床危险因子后,IL-6与卒中或全身性栓塞,严重出血,血管性死亡和复合血栓栓塞预后(缺血性卒中,全身性栓塞,心肌梗死,肺栓塞和血管性死亡)相关

冠心病患者动脉弹性与血清高敏C反应蛋白和基质金属蛋白酶9的相关性

 动脉系统作为一个整体,其结构和功能改变在心血管疾病发生发展中极其关键。近年研究发现动脉弹性可以反映动脉系统整体结构与功能变化,是早期血管病变的特异性和敏感性指标。它的改变早于疾病临床症状和体征出现并且是预测未来心血管事件的敏感指标。动脉弹性减退是多种危险因素对血管壁损害的综合反映[4] ,其中慢性系统性炎症反应是动脉结构与功能的重要影响因素。同时动脉粥样硬化被广泛地认为是一种慢性炎

7种方法降C反应蛋白 让心梗远离你

多年来医生都专注于用基本措施来评估患者的健康状况,如血压、体重、胆固醇水平等。但近年来更多的研究发现针对心脏健康出现了一种新的最有价值预测方法:C反应蛋白(CRP)。据menshealth.com网站报道,尽管早在1930年医生们就发现了这种由肝脏生成的血浆蛋白,但只是在前几年医学界才发现它很重要。现在医生已了解到体内的CRP水平能帮助评估慢性炎症及

PNAS:欺负人有益健康?

据《科学》(Science)网站报道,在学校里受欺负(Bullying)会使儿童产生长期的阴影,这些儿童长大以后更容易抑郁和产生自杀倾向。科学家们还发现,童年常被欺负的孩子长大以后更容易生病、出现头疼和胃部问题。现在一项新研究揭示了上述现象背后的原因,研究显示受欺负的儿童中疾病指标C反应蛋白( CRP )高于正常水平,而且他们长大以后依然如此。反倒是那些欺负人的孩子看起来更为健康。 在许多慢性病中

PLoS One:卒中后血浆CRP与卒中后疲劳并无相关

背景:脑卒中后疲劳是一种常见的、令人痛苦的问题,但很少有关于它的生物学机制的研究较少。这项队列研究是探讨脑卒中后C-反应蛋白(C反应蛋白)与卒中后疲劳的关系。方法:评估患者卒中后1月,6个月及12个月后,疲劳评估量表,卒中后疲劳定义,医院焦虑和抑郁量表,每天步数。收集患者血样,通过标准的CRP免疫测定CRP的水平。由Pearson相关和独立样本t检验判定每一时间点,CRP和疲劳之间的相关性。将抑郁